Card image cap
Parexel – n-Lorem collaboration for nano-rare therapies

Parexel, a global clinical research organisation, and n-Lorem, a nonprofit foundation, announced a new partnership in support of n-Lorem’s effort to discover and provide experimental antisense oligonucleotide (ASO) medicines to nano-rare disease patients (1 to 30 patients worldwide) for free, for life. Parexel brings significant expertise to the partnership, having managed approximately 400 rare disease clinical studies over the past five years that contributed to 17 drug approvals.

Content by Future Medicine

Disclaimer :
The author(s)' thoughts and opinions in this article are their own and do not necessarily reflect DocMode's viewpoint. The article is in no way created or edited by DocMode.

Supported by Koye Pharmaceuticals

Submit a Comment